Clinical trial NCT01228279: Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
Official title: Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: End-stage Renal Disease (ESRD)
Kidney Disease
Keywords: Peritoneal Dialysis
Dialysis Solutions
Artificial Kidney
Renal Replacement Therapy
Renal Dialysis
Sympathetic Nervous System
Leptin
Icodextrin
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: Heart and Stroke Foundation of Ontario
First posted: 2010-10-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis:

Patients starting peritoneal dialysis with a glucose-based regimen have high sympathetic activity in response to an increase in leptin and insulin. Converting patients from a regimen of only glucose containing dialysate to a regimen with non-glucose-based solution, icodextrin, will reduce the insulin and leptin levels and will reverse dialysis-induced increases in sympathetic activity.

Detailed description: Cardiovascular mortality remains higher among patients treated with peritoneal dialysis as compared to patients treated with hemodialysis. Sympathetic hyperactivity is considered a significant emerging risk factor for cardiovascular mortality among patients with ESRD (End-Stage Renal Disease). Sympathetic activity, via its hemodynamic effects and trophic effects, and in interaction with RAAS (Renin Angiotensin Aldosterone System), does play a major role in cardiac and vascular remodelling, development of LVH and vascular hypertrophy, as well as progression to CHF. Glucose-based dialysate induces hyperinsulinemia and hyperleptinemia. We propose that hyperleptinemia induced by glucose-based peritoneal solution is a significant contributing factor to sympathetic hyperactivity in ESRD patients treated with PD, and could be prevented by non-glucose-based PD solution such as icodextrin-based.

Adult patients with ESRD starting PD as their first renal replacement therapy modality will be studied. Patients will be recruited 1-3 weeks prior to starting PD treatment. At baseline, specific studies for microneurography (MSNA), fasting plasma insulin, leptin, catecholamines and brain natriuretic peptide (BNP) will be performed. EKG will be recorded and digitized for further assessment of heart rate variability using power spectral analysis. Extracellular fluid volume status will be assessed by bioelectrical impedance. Central vascular volume will be assessed from inferior vena cava (IVC) by heart ultrasound. Consequently 24-h ambulatory blood pressure monitoring(ABPM)and a 24-h urine collection for urea clearance and creatinine clearance will be done.

All participants into the study will receive a PD treatment for 6 weeks with standard glucose-based PD solution Dianeal. The specific studies are repeated at 6 weeks.Then, patients will be randomized to one of the two groups (arms). One group will continue with Dianeal PD solution for another 12 weeks. The other group will receive Dianeal during the day and Extraneal, icodextrin or non-glucose based solution, during the night only, for the next 12 weeks. The specific studies are repeated at 12 weeks after randomization (18 weeks of PD treatment).

Eligibility criteria: Inclusion Criteria:

* Adult (age 18 years and older)
* Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5

Exclusion Criteria:

* Diabetes Mellitus
* Acute coronary syndrome in the past 6 months
* Cardiac arrhythmias (2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)
* Symptoms suggestive of obstructive or central sleep apnea (with a score of \> 10 on Epworth sleepiness scale)
* Patients taking Clonidine
* Body mass index (BMI) \> 34
* Patients unable to give consent
* Pregnant women
* Patients with leg injury involving nerve damage
* Patients taking anticoagulant medication
* Patients with significant bleeding disorder or liver disorder
* Hemoglobin \<1.05 g/dl at the time of initiation of therapy
* patients with unilateral or bilateral nephrectomy
* Planned kidney transplant in the next 4 months
* Life expectancy under 6 months
* Oliguria (urine output less than 400 ml per day)

Primary outcomes:
measure: Changes in muscle sympathetic nerve activity(MSNA)
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in leptin levels
timeFrame: 6 weeks on PD and 18 weeks on PD
Secondary outcomes:
measure: Changes in blood pressure as assessed from 24-hour ambulatory blood pressure monitor (ABPM)
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in extracellular volume assessed by bioelectrical impedance (BIA)
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in heart rate variability
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in central intravascular volume assessed by cardiac ultrasound
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in plasma catecholamines levels
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in BNP (Brain Natriuretic Peptide)levels
timeFrame: 6 weeks on PD and 18 weeks on PD
measure: Changes in plasma insulin levels
timeFrame: 6 weeks on PD and 18 weeks on PD
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Ottawa Hospital Research Institute
state: Ontario
Study officials:
affiliation: Ottawa Hospital Research Institute
name: Marcel Ruzicka, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: